Products

By concentrating on diagnostic and pharmacogenetic products for critical care, Sirius is taking advantage of its internal expertise (see our selected publications), as well as addressing a large unmet medical need. The Company's first product is focused on sepsis, which affects 2.3 million people per year (in North America, Europe, and Japan) at a cost of approximately $22,000 per person. The Company has demonstrated that specific genotypes (or SNPs) can predict whether a patient will respond to certain sepsis treatments. Sirius believes that its test should be used by ICU and ER physicians dealing with septic patients, with the test results indicating the group of patients who will response most effectively to the drug treatment.

In addition to the Company's first product, the Company's platform can also be applied to (i) previously failed drugs, (ii) drugs in clinical trials, and (iii) new indications for currently approved drugs, ensuring a robust product pipeline for Sirius.